Results 261 to 270 of about 178,774 (332)

Intravitreal anti‐vascular endothelial growth factor injections and risks of stroke in patients with neovascular age‐related macular degeneration—A registry‐based cohort study

Acta Ophthalmologica, Volume 104, Issue 1, Page 98-105, February 2026.
Abstract Background Intravitreal Anti‐Vascular Endothelial Growth Factor (VEGF) rescues retinal vasculatures and prevents disease progression in patients with neovascular Age‐Related Macular Degeneration (nAMD). However, systemic anti‐VEGF may increase the risk of thromboembolic related complications including stroke and TIA. This study aims to explore
A. H. Falemban, K. Söderberg‐Löfdal, F. Jonsson, S. Almlöf‐Sarman, M. von Euler, I. Westborg   +5 more
wiley   +1 more source

FOLFIRI, FOLFOX4 AND BEVACIZUMAB TREATMENT IN A PATIENT ON MAINTENANCE HEMODIALYSIS WITH ADVANCED RECTAL CANCER SHOWING A SUBMUCOSAL TUMOR-LIKE APPEARANCE

, 2009
Tomokazu Tanaka, Keita Kai, Ryuichiro Samejima, S. Yakabe, Seiji Yunotani, Kohji Miyazaki   +5 more
openalex   +2 more sources

Impact of anti‐VEGF therapy versus laser therapy on mortality and treatment outcomes in retinopathy of prematurity: A systematic review and meta‐analysis

Acta Ophthalmologica, Volume 104, Issue 1, Page e1-e17, February 2026.
Abstract Purpose Retinopathy of prematurity (ROP) is a major cause of childhood blindness, and selecting the optimal treatment between anti‐vascular endothelial growth factor (anti‐VEGF) and laser therapy is crucial. Understanding their impact on key outcomes, particularly mortality, is essential for informed clinical decision‐making.
Wei‐De Wang, Ya‐Hsin Yao, Chiao‐Hsin Lan, Shih‐Heng Hung, Ta‐Hsin Tsung, Yann‐Guang Chen, Da‐Wen Lu, Jiann‐Torng Chen, Ke‐Hung Chien, Shu‐I Pao, Wei‐Ting Yen   +10 more
wiley   +1 more source

Synergistic anti-tumor effects of novel two-domain soluble Fms-like tyrosine kinase-1 and paclitaxel on three-dimensional breast cancer models: implications for targeted therapy. [PDF]

J Transl Med
Mutahar AZI, Dayal R, Salimath BP.
europepmc   +1 more source

Results of the treatment with intravitreal bevacizumab injection in branch retinal vein occlusion

, 2017
Osman Sayın
openalex   +2 more sources

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 3, Page 383-395, February 2026.
In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip   +9 more
wiley   +1 more source

Case Report: Biweekly TAS-102 and bevacizumab as maintenance therapy for recurrent and metastatic pseudomyxoma peritonei following palliative cytoreduction. [PDF]

Front Oncol
Wang B, Wang Y, Zhao D, Zhang H, Liu Q, Yu G, Jiao J.   +6 more
europepmc   +1 more source

Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study

Liver International, Volume 46, Issue 2, February 2026.
ABSTRACT Background/Aims Immune checkpoint inhibitors (ICIs) have transformed advanced HCC treatment. The benefit of sequential immunotherapy after prior ICI failure remains unclear. Given the expanded use of atezolizumab plus bevacizumab (Ate/Bev) over the past 5 years, we explored the real‐world outcomes of nivolumab plus ipilimumab (Nivo/Ipi) in ...
Jung Sun Kim, Jeffrey Wong, San‐Chi Chen, David Tai, Hannah Yang, Youngun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Chansik An, Su Jin Jang, Masatoshi Kudo, Ho Yeong Lim, Chan Kim, Thomas Yau, Hong Jae Chon   +15 more
wiley   +1 more source

Trends in Anti-Vascular Endothelial Growth Factor Injections Among Medicare Part B Beneficiaries in 2013-2021 and the Step Therapy Era. [PDF]

J Vitreoretin Dis
Bryan JM, Sheth N, Heiferman MJ.
europepmc   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 382-408, 15 January 2026.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source